CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer

Cameron M. Armstrong, Allen C Gao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The development of castration resistant prostate cancer and anti-androgen resistance remains one of the largest hurdles in the successful treatment of prostate cancer. Therefore, the identification of dysregulated pathways contributing to this resistance and determining ways to target these mechanisms is of utmost importance. In the recent publication in Cancer Research, Fong et al. identify a novel role for cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance. The authors demonstrate that CCN3 expression inhibits androgen receptor signaling and thereby suppresses enzalutamide-resistant prostate cancer cell proliferation, colony formation, and xenograft tumor growth. The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalJournal of Cell Communication and Signaling
Volume11
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Castration
Prostatic Neoplasms
Feedback
Cell proliferation
Androgen Receptors
Heterografts
Androgens
Tumors
Neoplasms
Cell Proliferation
MDV 3100
Growth
Research

Keywords

  • AR
  • CCN3
  • Enzalutamide
  • EZH2
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

CCN3-EZH2-AR feedback loop : new targets for enzalutamide and castration resistant prostate cancer. / Armstrong, Cameron M.; Gao, Allen C.

In: Journal of Cell Communication and Signaling, Vol. 11, No. 1, 01.03.2017, p. 89-91.

Research output: Contribution to journalArticle

@article{3ac5bb9ac08f460e893c384208021092,
title = "CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer",
abstract = "The development of castration resistant prostate cancer and anti-androgen resistance remains one of the largest hurdles in the successful treatment of prostate cancer. Therefore, the identification of dysregulated pathways contributing to this resistance and determining ways to target these mechanisms is of utmost importance. In the recent publication in Cancer Research, Fong et al. identify a novel role for cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance. The authors demonstrate that CCN3 expression inhibits androgen receptor signaling and thereby suppresses enzalutamide-resistant prostate cancer cell proliferation, colony formation, and xenograft tumor growth. The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer.",
keywords = "AR, CCN3, Enzalutamide, EZH2, Prostate cancer",
author = "Armstrong, {Cameron M.} and Gao, {Allen C}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s12079-017-0378-6",
language = "English (US)",
volume = "11",
pages = "89--91",
journal = "Journal of Cell Communication and Signaling",
issn = "1873-9601",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - CCN3-EZH2-AR feedback loop

T2 - new targets for enzalutamide and castration resistant prostate cancer

AU - Armstrong, Cameron M.

AU - Gao, Allen C

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The development of castration resistant prostate cancer and anti-androgen resistance remains one of the largest hurdles in the successful treatment of prostate cancer. Therefore, the identification of dysregulated pathways contributing to this resistance and determining ways to target these mechanisms is of utmost importance. In the recent publication in Cancer Research, Fong et al. identify a novel role for cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance. The authors demonstrate that CCN3 expression inhibits androgen receptor signaling and thereby suppresses enzalutamide-resistant prostate cancer cell proliferation, colony formation, and xenograft tumor growth. The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer.

AB - The development of castration resistant prostate cancer and anti-androgen resistance remains one of the largest hurdles in the successful treatment of prostate cancer. Therefore, the identification of dysregulated pathways contributing to this resistance and determining ways to target these mechanisms is of utmost importance. In the recent publication in Cancer Research, Fong et al. identify a novel role for cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance. The authors demonstrate that CCN3 expression inhibits androgen receptor signaling and thereby suppresses enzalutamide-resistant prostate cancer cell proliferation, colony formation, and xenograft tumor growth. The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer.

KW - AR

KW - CCN3

KW - Enzalutamide

KW - EZH2

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85014100468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014100468&partnerID=8YFLogxK

U2 - 10.1007/s12079-017-0378-6

DO - 10.1007/s12079-017-0378-6

M3 - Article

AN - SCOPUS:85014100468

VL - 11

SP - 89

EP - 91

JO - Journal of Cell Communication and Signaling

JF - Journal of Cell Communication and Signaling

SN - 1873-9601

IS - 1

ER -